Medicine for Gambling Disorder: FDA Approves Clinical Study Design

A significant breakthrough in addiction research is on the horizon as Hepion Pharmaceuticals, through its subsidiary Gravitas Life Sciences, has cleared major regulatory hurdles for a new medication. The candidate, known as GV104, is an investigational transmucosal buccal film designed to treat gambling disorder. This psychiatric diagnosis currently has no FDA-approved pharmacotherapy, leaving clinicians to rely solely on counseling and peer support. The FDA's Division of Psychiatry has now confirmed that the planned Phase 2 proof-of-concept design and the proposed disease severity assessment tools are generally appropriate.

This progress is particularly vital given the scale of the problem. The National Council on Problem Gambling (NCPG) estimates that 2 million U.S. adults meet the criteria for a severe gambling problem, while nearly 20 million reported problematic behaviors in a 2024 survey. The news from Red Bank, New Jersey, offers hope for a more comprehensive treatment approach that combines biological and behavioral therapies.

Numbers and facts

GV104 utilizes nalmefene, an opioid receptor modulator that acts as an antagonist at mu and delta receptors. While nalmefene was first approved in the U.S. in 1995 for reversing opioid effects, it has never been approved for gambling disorder. Hepion is utilizing the 505(b)(2) regulatory pathway, which allows for partial reliance on existing safety data from previously approved nalmefene products. The FDA indicated that existing nonclinical data appears sufficient to support clinical dosing for a 12-week duration in the upcoming Phase 2 trial.

"The Agency’s responses do two things for this program. They describe a 505(b)(2) route that relies in part on the FDA’s prior findings for an approved form of the product and confirm that the nonclinical and manufacturing work already on file under another IND can be cross-referenced." - Sireesh Appajosyula, CEO of Hepion Pharmaceuticals

Hepion anticipates filing a full Investigational New Drug (IND) application in 2027. The development process will incorporate FDA recommendations regarding dose-ranging and endpoint validation. Crucially, the company intends for GV104 to be used alongside psychosocial care rather than as a standalone replacement.

Background

Gambling disorder is classified in the DSM-5 as a non-substance-related addictive disorder characterized by persistent, recurrent gambling that causes significant distress. While most people gamble recreationally, those with the disorder face measurable mortality and severe life impairment. Despite academic interest in opioid modulators for over two decades, the path to a regulated medicine has been elusive until now.

Nir Barak, MD, Chief Medical Advisor at Gravitas Life Sciences, highlighted the importance of this regulatory feedback:

"The FDA has now described what a credible first study looks like, including that our proposed severity assessment is appropriate as the primary endpoint." - Nir Barak, MD, Chief Medical Advisor at Gravitas Life Sciences

Why it matters for German players

For players in Germany, this development is highly relevant as it underscores the global effort to combat gambling addiction. The German Interstate Treaty on Gambling 2021 (GlüStV 2021) already provides a robust safety net through the LUGAS system and a 1,000 Euro monthly deposit limit. However, for those who still struggle despite these restrictions, the prospect of a medical treatment adds a new layer of protection. A future medication could work in tandem with the German OASIS player blocking system, providing a biological tool to manage the intense cravings associated with addiction.

What it means for GGL-licensed casinos

Casinos holding a license from the Gemeinsame Glücksspielbehörde der Länder (GGL) are legally required to identify and assist at-risk players. The potential introduction of a medical treatment reinforces the status of gambling disorder as a serious medical condition. Licensed operators in Germany are better positioned than offshore sites to integrate such medical advancements into their social concept and player protection protocols. This development confirms that the strictly regulated German market is the right environment for players who value health-oriented safety standards over unregulated risks.